Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Review of Subject Recruitment Feasibility – V 2.0

Posted on By

BA-BE Studies: SOP for Review of Subject Recruitment Feasibility – V 2.0

Standard Operating Procedure for Review of Subject Recruitment Feasibility in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/037/2025
Supersedes SOP/BA-BE/037/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for reviewing and documenting the feasibility of recruiting healthy volunteers or study subjects for Bioavailability/Bioequivalence (BA/BE) studies in order to ensure timely completion of enrollment and avoid protocol deviations.

2. Scope

This SOP applies to all BA/BE studies planned by the organization or outsourced to CROs, and includes pre-study feasibility assessment, documentation, and monitoring of recruitment plans for healthy adult volunteers or special populations, if applicable.

3. Responsibilities

  • Clinical Project Manager: Coordinates feasibility assessments and compiles the feasibility report.
  • Site Coordinator/Investigator: Provides actual recruitment capability data based on past records.
  • Regulatory Affairs: Assesses if any restrictions apply (e.g., ethics caps on enrollment).
  • Medical Affairs: Reviews inclusion/exclusion criteria for practical applicability.
See also  BA-BE Studies: SOP for Protocol and SAP (Statistical Analysis Plan) Integration - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that a realistic and documented recruitment plan is in place before first subject screening is authorized.

5. Procedure

5.1 Initiation of Feasibility Assessment

  1. Initiate feasibility assessment during the protocol finalization phase or at least 4 weeks prior to planned study start.
  2. Use Annexure-1: Subject Recruitment Feasibility Questionnaire to collect site-specific information.

5.2 Data Collection Parameters

  1. Collect the following data from study sites:
    • Historical enrollment data for similar BA/BE studies
    • Average screening-to-enrollment ratio
    • Volunteer pool database size
    • Number of similar studies planned at the site during the same period
    • Availability of healthy volunteers meeting protocol criteria

5.3 Feasibility Analysis and Risk Assessment

  1. Review the protocol to identify restrictive criteria (e.g., BMI, lab values, washout requirements).
  2. Conduct SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis for each site.
  3. Document analysis using Annexure-2: Site Recruitment Feasibility Summary.
See also  BA-BE Studies: SOP for Study Timelines and Milestone Management - V 2.0

5.4 Recruitment Strategy and Contingency Planning

  1. Define the following in the recruitment plan:
    • Number of volunteers needed vs. site capacity
    • Backup sites (if applicable)
    • Contingency for screen failures and dropouts
    • Communication materials (approved recruitment flyers, SMS templates)
  2. Capture in Annexure-3: Study Recruitment Plan Log.

5.5 Approval and Filing

  1. Ensure all annexures are completed and approved by the Clinical Project Manager.
  2. File in the Trial Master File (TMF) and make available for ethics and regulatory review, if requested.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • TMF: Trial Master File
  • SWOT: Strengths, Weaknesses, Opportunities, Threats

7. Documents

  1. Subject Recruitment Feasibility Questionnaire – Annexure-1
  2. Site Recruitment Feasibility Summary – Annexure-2
  3. Study Recruitment Plan Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • EMA Clinical Trial Recruitment Guidance
See also  BA-BE Studies: SOP for Handling Confidentiality Agreements with Study Sites - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Subject Recruitment Feasibility Questionnaire

Question Response
Size of healthy volunteer database? 1200 active profiles
Previous BE study enrollments in 12 months? 5 studies, average 80 subjects each

Annexure-2: Site Recruitment Feasibility Summary

Site Name Strengths Weaknesses Opportunities Threats
Alpha Research Centre Large volunteer pool Limited staff on weekends High visibility via SMS Competing study same month

Annexure-3: Study Recruitment Plan Log

Activity Planned Date Owner Status
Flyer Approval from EC 18/04/2025 Regulatory Pending
SMS Campaign Launch 22/04/2025 Site Coordinator Scheduled

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial SOP New feasibility assessment policy QA Head
17/04/2025 2.0 Added SWOT analysis and SMS campaign planning Recruitment optimization QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Aerosol: SOP for Documenting Stability Testing Results – V 2.0
Next Post: Capsule: SOP for Documentation of Process Deviations in Capsule Production – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version